600276.SSJiangsu Hengrui Medicine Co., Ltd.
Oct 28, 2026 — Q3 2026 Earnings Release
Chart by TradingViewThe schedule
- Wed28Oct
Q3 2026 financial results, focusing on whether the growth in innovative drugs can offset the ongoing volume-based procurement (VBP) pressures on legacy generics.
- Tue15Dec
Conclusion of China's annual NRDL negotiations, revealing the new pricing and inclusion status for Hengrui's novel oncology and immunology assets.
- Tue20Apr
- Sat5Jun
